(Q33366441)

26 July 2017

title

Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer (English)

1 reference

26 July 2017

1 reference

1 reference

Beex LV

1

1 reference

26 July 2017

Hermus AR

2

1 reference

26 July 2017

Pieters GF

3

1 reference

26 July 2017

van Hoesel QG

4

1 reference

26 July 2017

Nooy MA

5

1 reference

26 July 2017

Mignolet F

6

1 reference

26 July 2017

publication date

1 January 1992

1 reference

European Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

28

1 reference

26 July 2017

issue

2-3

1 reference

26 July 2017

page(s)

686-690

1 reference

Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

Cancer, clinical pharmacology, and aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980126-1

7 January 2021

10.1016/S0959-8049(05)80126-1

Identifiers

DOI

1 reference

26 July 2017

1 reference